Advertisement
Australia markets close in 6 hours 12 minutes
  • ALL ORDS

    8,132.10
    +49.80 (+0.62%)
     
  • ASX 200

    7,863.70
    +49.30 (+0.63%)
     
  • AUD/USD

    0.6672
    +0.0001 (+0.01%)
     
  • OIL

    79.65
    -0.15 (-0.19%)
     
  • GOLD

    2,429.70
    -8.80 (-0.36%)
     
  • Bitcoin AUD

    107,082.08
    +7,740.52 (+7.79%)
     
  • CMC Crypto 200

    1,517.38
    +162.96 (+12.03%)
     
  • AUD/EUR

    0.6142
    +0.0004 (+0.07%)
     
  • AUD/NZD

    1.0924
    +0.0006 (+0.05%)
     
  • NZX 50

    11,698.80
    -36.91 (-0.31%)
     
  • NASDAQ

    18,674.19
    +127.96 (+0.69%)
     
  • FTSE

    8,424.20
    +3.94 (+0.05%)
     
  • Dow Jones

    39,806.77
    -196.82 (-0.49%)
     
  • DAX

    18,768.96
    +64.54 (+0.35%)
     
  • Hang Seng

    19,636.22
    +82.61 (+0.42%)
     
  • NIKKEI 225

    39,069.68
    +282.30 (+0.73%)
     

CareDx to Report First Quarter 2024 Financial Results

BRISBANE, Calif., April 29, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2024 after market close on Thursday, May 9, 2024. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Individuals interested in listening to the conference call may do so by dialing 1-800-343-4136 for domestic callers or 1-203-518-9843 for international callers. Please reference Conference ID: CareDx. To listen to a live webcast, please visit the investor relations section of CareDx’s website at: investors.caredxinc.com.

About CareDx – The Transplant Company

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240429253843/en/

Contacts

CareDx, Inc.
Investor Relations
Greg Chodaczek
investor@caredx.com